Literature DB >> 1850006

Functional similarities between human immunodeficiency virus type 1 and simian virus 40 kappa B proto-enhancers.

W Phares1, W Herr.   

Abstract

To search for broadly active enhancer elements within the human immunodeficiency virus type 1 (HIV-1) long terminal repeat, we have used a proto-enhancer amplification assay. In this assay, the enhancer region of simian virus 40 (SV40) is replaced by heterologous regulatory sequences. Upon passage in African green monkey kidney cells. SV40 growth revertants can arise by amplification (usually duplication) of active protoenhancers within the heterologous sequences. Most of the HIV-1 U3 regulatory sequences were assayed; only amplification of one or both of the HIV-1 enhancer core kappa B motifs consistently resulted in viable SV40 virus. Examination of the cell-specific enhancer activity of the individual HIV-1 kappa B proto-enhancers showed that, like the broadly active SV40 kappa B proto-enhancer (C proto-enhancer), they are all active in noninduced cell lines of either lymphoid (H9 and Jurkat) or nonlymphoid (HeLa and CV-1) origin. Unexpectedly, one of three kappa B point mutants that exhibit little or no activity in unstimulated cells is as highly induced in stimulated Jurkat cells as are the wild-type kappa B proto-enhancers. This point mutation shows that kappa B-related proto-enhancers can display markedly different activation properties in unstimulated cells yet still activate transcription to similar levels in stimulated cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850006      PMCID: PMC240567     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Characterization of cellular proteins recognizing the HIV enhancer using a microscale DNA-affinity precipitation assay.

Authors:  B R Franza; S F Josephs; M Z Gilman; W Ryan; B Clarkson
Journal:  Nature       Date:  1987 Nov 26-Dec 2       Impact factor: 49.962

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

4.  Oligonucleotide that binds nuclear factor NF-kappa B acts as a lymphoid-specific and inducible enhancer element.

Authors:  J W Pierce; M Lenardo; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

6.  Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1.

Authors:  K A Jones; J T Kadonaga; P A Luciw; R Tjian
Journal:  Science       Date:  1986-05-09       Impact factor: 47.728

7.  Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.

Authors:  J S McDougal; A Mawle; S P Cort; J K Nicholson; G D Cross; J A Scheppler-Campbell; D Hicks; J Sligh
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

8.  SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumours in transgenic mice.

Authors:  R D Palmiter; H Y Chen; A Messing; R L Brinster
Journal:  Nature       Date:  1985 Aug 1-7       Impact factor: 49.962

9.  Nuclear factor NF-kappa B can interact functionally with its cognate binding site to provide lymphoid-specific promoter function.

Authors:  T Wirth; D Baltimore
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

10.  Discrete elements within the SV40 enhancer region display different cell-specific enhancer activities.

Authors:  B Ondek; A Shepard; W Herr
Journal:  EMBO J       Date:  1987-04       Impact factor: 11.598

View more
  4 in total

1.  Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity.

Authors:  M C Estable; B Bell; A Merzouki; J S Montaner; M V O'Shaughnessy; I J Sadowski
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

2.  Transcriptional enhancers in animal development and evolution.

Authors:  Mike Levine
Journal:  Curr Biol       Date:  2010-09-14       Impact factor: 10.834

3.  The kappa B enhancer motifs in human immunodeficiency virus type 1 and simian virus 40 recognize different binding activities in human Jurkat and H9 T cells: evidence for NF-kappa B-independent activation of the kappa B motif.

Authors:  W Phares; B R Franza; W Herr
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

4.  Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.

Authors:  R Schreck; B Meier; D N Männel; W Dröge; P A Baeuerle
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.